{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T08:53:49Z","timestamp":1771577629066,"version":"3.50.1"},"reference-count":14,"publisher":"The Pediatric Pharmacy Association","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016]]},"abstract":"<jats:p>Postmarketing surveillance has associated meropenem with the development of hematologic abnormalities, including agranulocytosis, neutropenia, and leukopenia, but the exact incidence in children is unknown. The case describes a full-term, 26-day-old neonate admitted for a sepsis workup. She was found to have a blood culture positive for <jats:italic>Enterobacter cloacae<\/jats:italic> and suspected meningitis and was initiated on meropenem 40 mg\/kg\/dose intravenously every 8 hours. On day 14 of antibiotic treatment, the patient developed an isolated neutropenia with an absolute neutrophil count of 288 cells\/mm<jats:sup>3<\/jats:sup>. Meropenem was discontinued on hospital day 20, and a follow-up complete blood cell count 2 months later confirmed resolution of the hematologic abnormality. Clinicians should monitor complete blood cell counts diligently in children who receive large doses and prolonged courses of meropenem.<\/jats:p>","DOI":"10.5863\/1551-6776-21.4.353","type":"journal-article","created":{"date-parts":[[2016,9,27]],"date-time":"2016-09-27T19:25:50Z","timestamp":1475004350000},"page":"353-357","source":"Crossref","is-referenced-by-count":3,"title":["Meropenem-Induced Neutropenia in a Neonate"],"prefix":"10.5863","volume":"21","author":[{"given":"Joseph S.","family":"Van Tuyl","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, St. Louis College of Pharmacy, St. Louis, Missouri"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aubrey N.","family":"Jones","sequence":"additional","affiliation":[{"name":"Moses Cone Hospital, Greensboro, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter N.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Pharmacy: Clinical and Administrative Sciences, University of Oklahoma College of Pharmacy, Oklahoma City, Oklahoma"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3883","reference":[{"issue":"2","key":"i1551-6776-21-4-353-b1","series-title":"Clin Lab Haem","first-page":"99","article-title":"Nonchemotherapy drug-induced agranulocytosis: experience of the Strasbourg teaching hospital (1985\u20132000) and review of the literature","volume":"24","year":"2002","unstructured":"Andr\u00e8s\n              E, \n            \n              Kurtz\n              JE, \n            \n              Maloisel\n              F.\n            \n          \n          Nonchemotherapy drug-induced agranulocytosis: experience of the Strasbourg teaching hospital (1985\u20132000) and review of the literature. Clin Lab Haem. 2002;24(2):99\u2013106."},{"issue":"1","key":"i1551-6776-21-4-353-b2","series-title":"Curr Opin Hematol","first-page":"15","article-title":"Idiosyncratic drug-induced agranulocytosis or acute neutropenia","volume":"15","year":"2008","unstructured":"Andr\u00e8s\n              E, \n            \n              Maloisel\n              F.\n            \n          \n          Idiosyncratic drug-induced agranulocytosis or acute neutropenia. Curr Opin Hematol. 2008;15(1):15\u201321."},{"issue":"2","key":"i1551-6776-21-4-353-b3","series-title":"Ann Clin Lab Sci","first-page":"131","article-title":"Review: drug-induced neutropenia\u2013pathophysiology, clinical features, and management","volume":"34","year":"2004","unstructured":"Bhatt\n              V, \n            \n              Saleem\n              A.\n            \n          \n          Review: drug-induced neutropenia\u2013pathophysiology, clinical features, and management. Ann Clin Lab Sci. 2004;34(2):131\u2013137."},{"issue":"8","key":"i1551-6776-21-4-353-b4","series-title":"Arch Intern Med","first-page":"869","article-title":"Population-based drug-induced agranulocytosis","volume":"165","year":"2005","unstructured":"Iba\u00f1ez\n              L, \n            \n              Vidal\n              X, \n            \n              Ballarin\n              E, \n            \n              Laporte\n              JR.\n            \n          \n          Population-based drug-induced agranulocytosis. Arch Intern Med. 2005;165(8):869\u2013874."},{"key":"i1551-6776-21-4-353-b5","series-title":"Merrem package insert","year":"December 2013","unstructured":"Merrem package insert. Wilmington, DE: AstraZeneca Pharmaceuticals LP; December 2013."},{"issue":"suppl 1","key":"i1551-6776-21-4-353-b6","series-title":"Clin Infect Dis","first-page":"S41","article-title":"Update on the efficacy and tolerability of meropenem in the treatment of serious bacterial infections","volume":"47","year":"2008","unstructured":"Mohr\n              JF.\n            \n          \n          Update on the efficacy and tolerability of meropenem in the treatment of serious bacterial infections. Clin Infect Dis. 2008;47(suppl 1):S41\u2013S51."},{"issue":"8","key":"i1551-6776-21-4-353-b7","series-title":"Drug Safety","first-page":"657","article-title":"Safety profile of meropenem: an updated review of over 6000 patients treated with meropenem","volume":"30","year":"2007","unstructured":"Linden\n              P.\n            \n          \n          Safety profile of meropenem: an updated review of over 6000 patients treated with meropenem. Drug Safety. 2007;30(8):657\u2013668."},{"issue":"3","key":"i1551-6776-21-4-353-b8","series-title":"British J of Haematol","first-page":"984","article-title":"Bone marrow aplasia and meropenem in a paediatric patient [letter]","volume":"111","year":"2000","unstructured":"Estella\n              J, \n            \n              Villanueva\n              J, \n            \n              Calvo\n              M, \n          \n          et al. Bone marrow aplasia and meropenem in a paediatric patient [letter]. British J of Haematol. 2000;111(3):984\u2013990."},{"issue":"4","key":"i1551-6776-21-4-353-b9","series-title":"Eur J Clin Microbiol Infect Dis","first-page":"303","article-title":"Severe neutropenia in a patient treated with imipenem\/cilastatin [letter]","volume":"12","year":"1993","unstructured":"Fari\u00f1as\n              MC, \n            \n              Vega\n              TD, \n            \n              Garmendia\n              J, \n            \n              Gonzalez-Mac\u00cdas\n              J.\n            \n          \n          Severe neutropenia in a patient treated with imipenem\/cilastatin [letter]. Eur J Clin Microbiol Infect Dis. 1993;12(4):303\u2013304."},{"issue":"6","key":"i1551-6776-21-4-353-b10","series-title":"Arch Intern Med","first-page":"607","article-title":"Incidence of beta-lactam-induced delayed hypersensitivity and neutropenia during treatment of infective endocarditis","volume":"159","year":"1999","unstructured":"Olaison\n              L, \n            \n              Belin\n              L, \n            \n              Hogevik\n              H, \n            \n              Alestig\n              K.\n            \n          \n          Incidence of beta-lactam-induced delayed hypersensitivity and neutropenia during treatment of infective endocarditis. Arch Intern Med. 1999;159(6):607\u2013615."},{"issue":"3","key":"i1551-6776-21-4-353-b11","series-title":"Br J Haematol","first-page":"366","article-title":"Drug-induced agranulocytosis: prognostic factors in a series of 168 episodes","volume":"79","year":"1991","unstructured":"Juli\u00e1\n              A, \n            \n              Olona\n              M, \n            \n              Bueno\n              J, \n          \n          et al. Drug-induced agranulocytosis: prognostic factors in a series of 168 episodes. Br J Haematol. 1991;79(3):366\u2013371."},{"issue":"1","key":"i1551-6776-21-4-353-b12","series-title":"J Infect Dis","first-page":"90","article-title":"Inhibition of granulopoiesis in vivo and in vitro by beta-lactam antibiotics","volume":"152","year":"1985","unstructured":"Neftel\n              KA, \n            \n              Hauser\n              SP, \n            \n              M\u00fcller\n              MR.\n            \n          \n          Inhibition of granulopoiesis in vivo and in vitro by beta-lactam antibiotics. J Infect Dis. 1985;152(1):90\u201398."},{"issue":"1","key":"i1551-6776-21-4-353-b13","series-title":"Br J Haematol","first-page":"9","article-title":"Cephalosporin-induced immune neutropenia","volume":"59","year":"1985","unstructured":"Murphy\n              MF, \n            \n              Metcalfe\n              P, \n            \n              Grint\n              PC, \n          \n          et al. Cephalosporin-induced immune neutropenia. Br J Haematol. 1985;59(1):9\u201314."},{"issue":"2","key":"i1551-6776-21-4-353-b14","series-title":"Clin Pharmacol Ther","first-page":"239","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","year":"1981","unstructured":"Naranjo\n              CA, \n            \n              Busto\n              U, \n            \n              Sellers\n              EM, \n          \n          et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239\u2013245."}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"link":[{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/21\/4\/article-p353.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/meridian.allenpress.com\/jppt\/article-pdf\/21\/4\/353\/1787169\/1551-6776-21_4_353.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/21\/4\/article-p353.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/21\/4\/article-p353.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:40:28Z","timestamp":1747356028000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/21\/4\/article-p353.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":14,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-21.4.353","relation":{},"ISSN":["1551-6776"],"issn-type":[{"value":"1551-6776","type":"print"}],"subject":[],"published":{"date-parts":[[2016]]}}}